Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Pilot in Advanced Gastroesophageal Adenocarcinoma
NCT03395847Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2018
- Primary completion
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in gastroesophageal adenocarcinoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Objective Response Rate up to 4 years. Started Feb 2018; status: completed.
02
Drugs
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT03395847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03395847.